Teva is getting close to FDA approval for a drug with the sales potential of a billion dollars

The FDA accepted Teva's application for the approval of the new Tourette syndrome treatment for children, with a decision expected to be made in the first quarter of 2027. • The drug may offer an alternative to existing treatments for children, some of which are accompanied by significant side effects.